Original Articles

Antiproliferative Effects of Selected Chemotherapeutics in Human Ovarian Cancer Cell Line A2780

Kateřina Caltová, Miroslav Červinka

Charles University in Prague, Faculty of Medicine in Hradec Králové, Czech Republic: Department of Medical Biology and Genetics

Summary: The aim of our study was to determine the effect of selected cytostatics on a human ovarian cancer cell line A2780 as a model system for ovarian cancer treatment. This cell line is considered cisplatin-sensitive. Panel of tested cytostatics included cisplatin, paclitaxel, carboplatin, gemcitabine, topotecan and etoposide. These cytostatics have a different mechanism of action. To evaluate cytotoxic potential of the tested compounds, the methods measuring various toxicological endpoints were employed including morphological studies, MTT assay, dynamic monitoring of cell proliferation with xCelligence, cell cycle analysis, caspase 3 activity and expression of proteins involved in cell cycle regulation and cell death. The A270 cell line showed different sensitivity towards the selected cytostatics, the highest cytotoxic effect was associated with paclitaxel and topotecan.

Key words: A2780; Cytostatics treatment; Chemosensitivity testing; Cisplatin; Topotecan

Introduction

Ovarian cancer is the fifth most common cancer in women and the leading cause of death from gynecologic malignancies. Annually about 1200 new cases of this malignancy are diagnosed in the Czech Republic and about 700 women die (8). Ovarian tumours are classified as chemosensitive tumours but not chemocurable tumours. Therapeutic treatment of ovarian cancer patients involves surgery with maximal cytoreduction, subsequent chemotherapy and exceptionally also radiotherapy (7). Administration of platinum derivative and paclitaxel in combination constitutes first line standard for patients with advanced epithelial ovarian cancer (30), yielding response in about 80% of patients (4).

In cases of recurrence the treatment is problematic because there is a lack of therapeutic standard. Retrospective studies of platinum-based second-line therapies have identified two subgroups of patients with recurrent ovarian cancer: those with platinum-sensitive disease (DFI > 6 months) when platinum derivatives can be used again and those with platinum-resistant disease (DFI ≤ 6 months) when platinum derivatives are not used in second-line chemotherapy again (20, 29). In those cases second and further lines of chemotherapy include paclitaxel alone, topotecan, liposomal doxorubicin or gemcitabine (7).

Cytotoxic mechanism-oriented studies of clinically applied agents are often carried out on model systems in vitro to provide mechanistic feedback into the efficiency and usefulness of particular chemotherapeutic regimens. Here we used human epithelial ovarian cancer cell line A2780, which is considered as cisplatin sensitive (according to the ECACC catalog, cell line code: 93112519). This cell line was employed as a model for further investigation of the inhibitory and proapoptotic activities of selected cytostatics.

Materials and methods

Cell line

Human ovarian cancer cell line A2780 was obtained from European Collection of Animal Cell Cultures (ECACC, Porton Down, Wiltshire, England, Cat. No 93112519). Cells were grown as adherent cultures in medium RPMI 1640 + 2 mM glutamine and 10% fetal bovine serum at 37 °C and 5% CO₂.

Cytostatic treatment

The concentration range of selected cytostatics (Tab. 1) was chosen according to the schedule employed in previous studies using clinical samples (5). Every cytostatic was tested in six concentrations. The highest concentrations (c₁) of tested cytostatics were as follow: cisplatin CisPt (EBEWE Pharma Ges.m.b.H, Nfg.KG, Austria) 100 µg/ml, paclitaxel PTX (Pliva-Lachema a.s., Czech Republic) 50 µg/ml, carboplatin CBdCa (EBEWE Pharma Ges.m.b.H, Nfg.KG, Austria) 100 µg/ml, gemcitabine Gmc (Gemzar...
200 mg, Eli Lilly, s.r.o., Czech Republic) 300 µg/ml, topotecan Topo (Hycamtin 4 mg, GlaxoSmithKline, UK) 50 µg/ml and etoposide Etop (Teva Pharmaceuticals, s.r.o., Czech Republic) 50 µg/ml. Lower concentrations were prepared using dilution factor of four. The middle inhibition concentration \( c_4 \) for each cytostatic was chosen for further studies. We use general term “\( c_4 \)” because its value is different for tested cytostatics. Concentrations \( c_4 \) were nearest to the EC50 values for selected cytostatics obtained in testing of clinical samples.

**MTT assay**

Effect of tested cytostatics on metabolic activity of treated cells A2780 was evaluated by MTT assay and expressed as the EC50 values. MTT assay was carried out as described before (5).

**xCELLigence**

xCELLigence system (Roche) is use to monitor cytotoxicity, using electronic cell sensor array technology. xCELLigence E-plates were filled with 100 µl RPMI medium/well and the background signal was determined. Next, 100 µl of cell suspension was added in to each well (25,000 cells/well). Cells were allowed to adhere (30 min at room temperature), E-plates were placed in the instrument and cell proliferation was monitored for 24 h. Thereafter, tested cytostatics according to selected concentration ranges were added to cultivation media and cell index was recorded for next 72 h. Together six concentrations of each cytostatic drug were tested (Tab. 1). EC50 values were determined for each cytostatic after 72 h of treatment.

**Morphological studies**

10 ml of A2780 cell suspension in a density of \( 2 \times 10^5 \) cells/ml were seeded into small tissue culture flasks and cultivated at 37 °C and 5% CO2 for 24 hours. Next, cultivation medium was removed and fresh medium with cytostatics at tested concentration ranges was added. At time intervals of 0 h, 24 h, 48 h, and 72 h, photographs of control and treated cells were obtained using Olympus IX70 microscope and JVC color video camera (Victor Company of Japan) at magnification of 400×. Photographs were analysed by LUCIA (NIS Elements).

**Cell cycle analysis**

Control and treated cells were trypsinised and harvested to the centrifuge tubes. After the centrifugation cells were rinsed with PBS and then fixed with 70% ice-cold ethanol. Fixed samples were stored in 4 °C overnight. After, cells were washed with PBS and the cell number was adjusted to \( 1 \times 10^6 \) cells per ml. Cells were incubated with 0.5 ml of phosphate-citrate buffer (0.2 M Na2HPO4, 0.1 M citrate, pH 7.8), washed with PBS and stained with 0.5 ml of Vindelov’s solution (1.2 g/l TRIS, 0.6 g/l NaCl, 0.01 g/l RNase, and 0.05 g/l propidium iodide) at 37 °C for 1 h in dark. Stained samples were analyzed on flow cytometer (Cell Lab Quanta SC MPL Flow Cytometer, Beckman Coulter, USA) equipped with 488 nm laser in FL2 channel.

**Western blot analysis**

Control and treated cells were trypsinized after 24 h incubation interval, washed with PBS and centrifugated 5 min at 1000 rpm and 4 °C. Pellets were resuspended in 5 ml of ice-cold lysis buffer (137 mmol NaCl, 10% glycerol, 1% n-octyl-β-D-glucopyranoside, 50 mmol NaF, 20 mmol Tris, 1 mmol sodium orthovanadate, Complete TM Mini). Cell lysates were boiled for 5 min at 95 °C in SDS sample buffer (Tris-HCl pH 6.81, 2-mercaptoethanol, 10% glycerol, SDS, 0.1% bromphenol blue). Samples were loaded onto a 15% polyacrylamide gel. All lysates contained equal amount of protein, 40 µg, and it was determined by BCA assay. Electrophoretically separated proteins were transferred to PVDF membrane (100 V, 1 h) and then incubated at 25 °C for 1.5 h with a 5% non fat dry milk, 10 mmol Tris-HCl (pH8.0), 150 mM NaCl and 0.1% Tween 20 (TBST – Tris-Buffered Saline Tween 20). Membranes were then incubated with primary antibodies (polyclonal rabbit anti-Cdc25A

<table>
<thead>
<tr>
<th>Concentration</th>
<th>Cytostatics</th>
</tr>
</thead>
<tbody>
<tr>
<td>( c_1 ) (µg/ml)</td>
<td>CisPt 50, PTX 50, CBDCA 100, Gmc 300, Topo 50, Etop 50</td>
</tr>
<tr>
<td>( c_2 ) (µg/ml)</td>
<td>25 12.5 25 75 12.5 12.5</td>
</tr>
<tr>
<td>( c_3 ) (µg/ml)</td>
<td>6.25 3.13 6.25 18.75 3.13 3.13</td>
</tr>
<tr>
<td>( c_4 ) (µg/ml)</td>
<td>1.56 0.78 1.56 4.69 0.78 0.78</td>
</tr>
<tr>
<td>( c_5 ) (µg/ml)</td>
<td>0.39 0.20 0.39 1.17 0.20 0.20</td>
</tr>
<tr>
<td>( c_6 ) (µg/ml)</td>
<td>0.10 0.05 0.10 0.29 0.05 0.05</td>
</tr>
</tbody>
</table>

Tab. 1: Concentration ranges of tested cytostatics
1:100, polyclonal rabbit anti-cyclin B1 1:200, monoclonal mouse anti-cyclin D1 1:100, monoclonal mouse anti-PCNA 1:1000, rabbit anti-BAX 1:200, monoclonal rabbit anti-XIAP 1:100, monoclonal mouse anti-p53 1:100, monoclonal mouse anti-β-actin 1:10,000 (all from Cell Signaling Technology, Inc., USA) and monoclonal mouse anti-p21 1:200 (Santa Cruz Biotechnology, Santa Cruz, USA) at 4 °C overnight followed by five 6 min washes in TBST. Then membranes were incubated with secondary peroxidase-conjugated antibodies (1:1000, 1 h, 25 °C; Dako, Denmark), washed with TBST and the signal was developed by chemiluminescence detection kit (ECL, Boehringer Mannheim-Roche, Switzerland). β-actin was used as a loading control. Density of protein-specific signals was evaluated by Carestream molecular imaging software (Carestream Health, Inc., USA).

**Caspase 3 activity**

Control and treated cells were harvested by centrifugation (600 × g, 5 min) and lysed on ice for 20 min in a lysis buffer (50 mM HEPES, 5 mM CHAPS, 5 mM DTT). Cell lysates were centrifuged at 14,000 × g, 10 min and 4 °C, the supernatants were collected and stored at –80 °C. The caspase 3 activity was measured in 96-well microtiter plates with the use of a kinetic fluorimetric assay based on the hydrolysis of the peptide substrate Ac-DEVD-AMC by caspase 3. This results in the release of the fluorescent 7-amino-4-methylcoumarin (AMC) moiety. Ac-DEVD-CHO, a specific inhibitor of caspase 3, was used to confirm the specificity of the cleavage for caspase 3. Fluorescence was measured by photometer at excitation λ 360 nm and emission λ 465 nm. The concentration of the AMC released was calculated from a standard curve constructed with known concentrations of AMC. Caspase 3 activity was expressed as nmol AMC/min/mg protein. Proteins were determined spectrophotometrically with the use of bicinchoninic acid and bovine serum albumin as a standard.

**Statistical analysis**

Statistical analysis was carried out using the Student’s t-test. Results were considered statistically significant at p < 0.05.

**Results**

**Cell proliferation assays**

**MTT assay**

The effect of tested cytostatics on proliferation of A2780 cells was evaluated by MTT cell proliferation assay (Fig. 1, Tab. 2). The highest inhibition of proliferation showed cells treated with paclitaxel, gemcitabine and topotecan. The cell cultures were least sensitive to carboplatin and etoposide treatment. The middle inhibition concentration c4 for each cytostatic was chosen for further studies (morphological analysis, cell cycle and cell death analysis).

<table>
<thead>
<tr>
<th>Cytostatics</th>
<th>EC50 ± SD (MTT)</th>
<th>EC50 ± SD (xCELLigence)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CisPt</td>
<td>1.36E+00 ± 7.55E-01</td>
<td>5.59E-01 ± 1.87E-02</td>
</tr>
<tr>
<td>PTX</td>
<td>7.81E-01 ± 4.67E-01</td>
<td>4.72E-03 ± 5.65E-04</td>
</tr>
<tr>
<td>CBDCa</td>
<td>1.37E+01 ± 5.16E+00</td>
<td>3.83E+01 ± 6.06E+00</td>
</tr>
<tr>
<td>Gmc</td>
<td>NA</td>
<td>1.54E-02 ± 6.17E-03</td>
</tr>
<tr>
<td>Topo</td>
<td>NA</td>
<td>1.47E-02 ± 2.60E-03</td>
</tr>
<tr>
<td>Etop</td>
<td>1.88E+00 ± 4.18E-01</td>
<td>2.92E-01 ± 3.25E-02</td>
</tr>
</tbody>
</table>

CisPt – cisplatin, PTX – paclitaxel, CBDCa – carboplatin, Gmc – gemcitabine, Topo – topotecan, Etop – etoposide. EC50 values from MTT are means of nine independent experiments and EC50 values from xCELLigence are means of three independent experiments. SD – standard deviation, NA – not applicable: Our model cell line A2780 is very sensitive to gemcitabine and topotecan treatment. EC50 values from MTT assay are not countable for these cytostatics. These values are smaller than minimal tested concentrations of cytostatics.

**xCELLigence**

Antiproliferative effect of tested cytostatics in A2780 cells was further evaluated by the xCELLigence RTCA software for
individual cytostatics after 72 h of treatment (Tab. 2). The highest EC50 values were reached for carboplatin, high EC50 values were acquired also after cisplatin and etoposide treatment. The lowest EC50 values were detected after paclitaxel treatment.

**Morphological studies**

To evaluate morphological changes of cells treated with cytostatics, a time-lapse study of control and treated cells were observed by Olympus IX70 at magnification 400× in time intervals 0 h, 24 h, 48 h, and 72 h. While control samples proliferated and reached confluence by 72 h of cultivation, cells treated with cytostatics gradually lost their adherence to the surface and displayed intensive blebbing typical for apoptotic cell death. The earliest changes in morphology were detected in case of paclitaxel, followed by gemcitabine, topotecan and etoposide (Fig. 2).

**Cell cycle analysis**

**Cell cycle distribution**

Tested cytostatics in the middle inhibition concentration (c4) changed the cell cycle distribution of the A2780 cells (Fig. 3). Cisplatin, carboplatin and gemcitabine increased the proportion of cells in G1/S phases of the cell cycle. Topotecan and etoposide induced accumulation of cells in S phase, this effect was more prolonged in case of topotecan. Paclitaxel blocked the cell cycle in G2 phase up to 6 hours after treatment, followed by increase in S phase at 12 h and G1 phase at 24 h.

![Fig. 2: Morphological changes in A2780 cells treated with the middle inhibition concentration of selected cytostatics (c4) for 72 h. Magnification 400×. C – control, CisPt – cisplatin, PTX – paclitaxel, CBDCA – carboplatin, Gmc – gemcitabine, Topo – topotecan, Etop – etoposide. Experiments were three times repeated](image-url)
Fig. 3: Changes in cell cycle distribution of A2780 cells treated with the middle inhibition concentration ($c_\text{m}$) of tested cytostatics during 24 h. Experiments were three times repeated.
Cell cycle protein analysis

Cytostatics in selected concentration (c4) influenced the protein expression of cell cycle markers after 24 h of treatment as shown in Fig. 4a. Cdc25A protein phosphatase was up-regulated in all treated samples, the highest values were detected in case of topotecan and gemcitabine, followed by etoposide and carboplatin. Cyclin B1 expression was up-regulated after treatment with all tested cytostatics with the exception of etoposide, the most prominent increase was associated with gemcitabine followed by carboplatin, paclitaxel, topotecan and cisplatin. Cyclin D1 expression was increased after topotecan and etoposide treatment, but decreased after paclitaxel, carboplatin and mainly gemcitabine treatment. p21 was up-regulated after the treatment with topotecan, etoposide, paclitaxel and gemcitabine. PCNA expression was increased in cells treated with gemcitabine, etoposide, carboplatin, topotecan and moderately with paclitaxel.

Cell death analysis

Western blot

Cytostatics tested in middle concentration (c4) influenced the expression of apoptotic markers as shown in Fig. 4b. Bax expression was decreased in cases of carboplatin and paclitaxel. XIAP as an inhibitor of apoptosis proteins, especially caspases 3 and 7, was up-regulated after gemcitabine, etoposide, paclitaxel and carboplatin treatment, but down-regulated in case of topotecan treatment. The expression of p53 was up-regulated after topotecan treatment.

Caspase 3 activity

Selected cytostatics tested in middle inhibition concentration (c4) affected the activity of caspase 3 during 72 h of incubation. The lowest activity of caspase 3 was detected after carboplatin treatment. On the contrary, the quickest and the highest activity of caspase 3 was detected after topotecan treatment (Fig. 5). In case of the other tested cytostatics the highest activity of caspase 3 was detected after 24 h from the treatment.

Discussion

This study evaluates the anti-proliferative and cytotoxic effect of a panel of selected cytostatics in a model ovarian carcinoma cell line A2780. Of these cytostatic, carboplatin, cisplatin and paclitaxel are used in first-line ovarian cancer treatment, while gemcitabine, topotecan and etoposide are used in alternative regimen or in monotherapy of second- and higher lines of ovarian cancer treatment (24). The selected cytostatics have different mechanisms of action. The alkylating agents platinum coordination complexes cisplatin and carboplatin form inter- and intrastrand DNA.
crosslinks (9). The taxan derivative paclitaxel blocks the cell division by stabilization of microtubuli. Chromosomes are thus unable to achieve a metaphase spindle configuration. This blocks progression of mitosis and prolonged activation of the mitotic checkpoint triggers apoptosis or reversion to the G-phase of the cell cycle without cell division (3, 6). Gemcitabine, the pyrimidine analogue, inhibits processes required for DNA synthesis (31). The topoisomerase I inhibitor topotecan intercalates between DNA bases. This intercalation disrupts the DNA duplication machinery when it reaches a site where topotecan is intercalated. This disruption prevents DNA replication, and ultimately leads to cell death (35). Finally the topoisomerase II inhibitor etoposide forms a ternary complex with DNA and the topoisomerase II enzyme, preventing re-ligation of the DNA strands. This causes errors in DNA synthesis and promotes apoptosis of the cell (19).

To describe the anti-proliferative effect of the selected cytostatics we employed the MTT assay that detects the activity of mitochondrial succinate dehydrogenase (13) and combined it with the dynamic monitoring of cell proliferation with the xCELLigence system. This new method has proven to be a valuable tool for label-free real time monitoring of cellular proliferation and adhesion that has some advantages over the standard end-point assays and is now widely used to monitor the compound-mediated cytotoxicity (32). This study showed, that EC50 values obtained with xCELLigence were lower compared to those obtained with the MTT assay, so xCELLigence detected the anti-proliferative effect of the tested drugs with higher sensitivity.

The concentration range of tested cytostatics was chosen according to the schedule employed in the previous testing of the clinical samples (5). The highest anti-proliferative effect was observed with paclitaxel, gemcitabine and topotecan. For further experiments we selected concentrations presented as c4, nearest to the EC50 values for selected cytostatics obtained in testing of clinical samples. Selected cytostatics in tested concentration changed the cell cycle distribution during 24 h treatment of A2780 cells. Cisplatin, carboplatin and gemcitabine increased the proportion of cells in G1/S phases of the cell cycle. All these cytostatics finally inhibit DNA synthesis and this correlates with the cell cycle distribution. Topotecan and etoposide induced accumulation of cells in S phase, this effect was more prolonged in case of topotecan. Topotecan inhibits topoisomerase I and etoposide inhibits topoisomerase II. Both enzymes are needed during DNA replication and their inhibition leads to the inhibition of DNA synthesis. Treatment with 0.78 µg/ml (c4) paclitaxel blocked the cell cycle in G2 phase up to 6 hours after treatment, followed by increase in S phase at 12 h and G1 phase at 24 h. This finding correlates with the mechanism of action of paclitaxel, which stops cell cycle in G2/M phase. This behaviour most probably reflects the dynamics of the cell proliferation and cell death during the 24 h interval and is caused by the depletion of cells in G2 phase due to apoptosis.

![Fig. 5: Changes in caspase 3 activity in A2780 cell line treated with the middle inhibition concentration (c4) of tested cytostatics during 72 h. CisPt – cisplatin, PTX – paclitaxel, CBdCA – carboplatin, Gmc – gemcitabine, Topo – topotecan, Etop – etoposide. + significantly higher against control in 6 h time interval, * significantly higher against control in 12 h time interval, ** significantly higher against control in 24 h time interval, # significantly higher against control in 48 h time interval, ˜ significantly higher against control in 72 h time interval. Student’s t-test, p < 0.05 was considered as statistically significant. Results are means of two independent experiments.](image)
Protein expression detected by western blot was changed after the cytostatics treatment. Cdc25A protein phosphatase plays a critical role in activating cyclin-dependent kinases (CDKs) and induces G1/S phase cell cycle transit. Normal cell cycle progression leads to increased cdc25A expression (37). Its expression was most prominently up-regulated in topotecan-treated cells, higher expression in comparison to control samples was also detected after carboplatin, gemcitabine and etoposide treatment. After 24 h from the treatment cells were not inhibited in G1/S phase cell cycle progression. Upregulation of mitotic cyclin B1, marking the block in the transition into the mitotic phase, was detected in all treated samples with the exception of etoposide. Cell cycle distribution after etoposide treatment showed about 60% of cells accumulated in G2 phase. Cyclin D1 regulates cyclin-dependent kinases and transition to G1/S phase of cell cycle (22). Its expression was decreased in gemcitabine-treated cells, which correlates with the increase in G1 phase observed during cell cycle distribution analysis. Protein p21 is an inhibitor of cyclin-dependent kinases that inhibits the progression of cells through the cell cycle. Its expression is up-regulated by p53 in response to DNA damage (12, 15). Increased expression of p21 in A2780 cells was detected after topotecan and etoposide treatment in the 24 h time interval. In this time, the p53 expression was significantly increased only in topotecan-treated cells. The proliferating cell nuclear antigen PCNA is a member of the DNA sliding clamp family of proteins that assist in DNA replication (25). It is a well-accepted marker of cell proliferation, but it is also required for the DNA repair (33, 16). In case of A2780 cells, PCNA expression was increased after carboplatin, gemcitabine, topotecan and etoposide treatment. X-linked inhibitor of apoptosis protein XIAP binds to and inhibits caspases 3, 7, and 9 (14). It blocks the apoptosis as a result of the inhibition of effector caspases. Its highest expression was detected in etoposide-treated cells and then after gemcitabine, carboplatin and paclitaxel treatment too, which correlates with relatively lower caspase 3 activity observed after the treatment with these cytostatics in comparison to the others. XIAP expression was decreased in topotecan-treated cells in comparison to control samples, and topotecan-treated cells also showed the highest expression of p53 protein and highest activity of caspase 3.

Bcl-2 and Bax are transcription targets for tumor suppressor protein p53. The expression of proapoptotic protein Bax can be induced by cytostatics (1). Protein Bax promote the activity of effector caspase 3 and thereby apoptosis. Bax as a member of BCL2 protein family is an activator of apoptosis. Expression of Bax was significantly decreased in carboplatin-treated A2780 cells. This is in correlation with the activity of caspase 3, which was lowest after carboplatin treatment.

Activation of caspases is associated with induction of apoptosis. Caspase 3, one of the effector caspases, induces proteolytic activation of many cell proteins, apoptosis-associated chromatin migration, DNA fragmentation and nuclear collapse (34). Quantifiable markers of apoptosis such as caspase 3 activation have the potential to predict the clinical response to chemotherapy (17). We detected significantly elevated levels of activated caspase 3 in A2780 cells after 24 h treatment with tested cytostatics, with the highest activity observed in case of topotecan, followed by gemcitabine, etoposide and cisplatin. Paclitaxel, which showed the highest antiproliferative effect in vitro and xCELLigence assays as well as in the morphological studies, did not prove that effective in elevating caspase 3 activity in treated cells. The lowest caspase 3 activity detected was associated with carboplatin treatment, which is in correlation with the results found in literature (27, 28).

Several studies compared the reactivity of platinum derivatives and paclitaxel (first line cytostatics treatment) in both sensitive and resistant model cell lines (2, 18, 11). A2780 cells as a cisplatin-sensitive cell line has been used as a model in in vitro ovarian cancer studies, that tested anti-proliferative effects of platinum derivatives (21), paclitaxel (38) and the combination of these cytostatics (23). In our study we tested wider panel of cytostatics that covers the first and second line drugs employed in clinics. Results of our in vitro chemosensitivity testing in A2780 model cell line showed for the first time that the most effective antiproliferative effect was associated with topotecan. Topotecan in comparison to other selected cytostatic drugs also induced the highest expression of key molecule p53, low expression of XIAP or the highest detected caspase 3 activity. Topotecan, topoisomerase I inhibitor, has been used for the treatment of recurrent metastatic ovarian cancer and also many other types of cancer. Topotecan has demonstrated antitumour activity in platinum-sensitive, platinum-resistant, and paclitaxel-resistant tumours (10, 26, 36). Effectivity of topotecan in our model cell line correlates with results of our previous study using cells isolated from clinical samples (5), which may support the idea to use this cytostatic in the first-line chemotherapy treatment of ovarian cancer patients.

Conclusions

In this study we tested a wide panel of cytostatics in a model ovarian cancer cell line A2780. Selected cytostatics cover the first- and second-line drugs employed in treatment of ovarian cancer and included cisplatin, paclitaxel, carboplatin, gemcitabine, topotecan and etoposide. The results showed time- and dose-dependent toxicity of model A2780 cell line to selected cytostatics, the most effective antiproliferative effect was associated with topotecan treatment, which correlates with results of our previous study using cells isolated from clinical samples.

Acknowledgements

This work was supported by project PRVOUK P37/01.
References


20. Gore ME, Fryatt I, Wiltshaw E et al. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 1990; 36: 207–11.


Received: 14/06/2012
Accepted in revised form: 22/08/2012

Corresponding author:

Mgr. Kateřina Calťová, Charles University in Prague, Faculty of Medicine in Hradec Králové, Department of Medical Biology and Genetics, Simková 870, 500 38 Hradec Králové, Czech Republic; e-mail: brigulovak@lfhk.cuni.cz